Survodutide
Shop SurvodutideAlso called: Survodutide UK & Lab UK
Survodutide is a man-made medicine-like chemical called a peptide. It is a small chain of building blocks, like a tiny piece of a protein. Scientists made it to act like two natural body chemicals at once. It is not approved for sale to people yet. It is being studied in labs and in medical research trials.
In studies, survodutide seems to help people feel less hungry and may help the body burn more energy. It works by copying two messengers. One messenger tells the brain the stomach is full. The other one, called glucagon, may help the body use stored fat. Researchers are testing it to see if it can help with weight and with a liver problem caused by too much fat in the liver.
There is still a lot we do not know. Big studies are still going on, so scientists do not yet know all the good and bad effects. Like similar medicines, it may cause stomach upset, such as feeling sick. You should never use it without a doctor, because it has not been checked and approved for safety yet.
Benefits
What Survodutide Helps With
The benefits people report — backed by research.
Glycemic & metabolic (4)
Renal & hepatic (3)
Anti-fibrotic (2)
Cardiovascular & vascular (2)
Weight management (1)
More reported benefits (3)
Free: The Peptide Stack Cheat-Sheet
You just read the research on Survodutide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
How People Use It
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
- Highest dose (specific mg not provided) 72/100Rated 72/100Source typeEstablished referenceIndependent sources16Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Safety
Known Side Effects
Adverse effects reported in the research and by community use.
- Mild to moderate gastrointestinal problemsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ biopharmadive.com
- Discontinuation due to side effects during dose escalation periodModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ biopharmadive.com
- InfectionsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pharmaphorum.com
- Cytokine release syndromeModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pharmaphorum.com
- Gastrointestinal issuesModerateReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com↗ withpower.com
- Decreased appetiteMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com↗ withpower.com
- Transient gastrointestinal issuesMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Gastrointestinal adverse eventsMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com↗ peptidepedia.org
- Mild to moderate treatment-emergent adverse events in renal impairment patientsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Get Survodutide
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
News
Latest on Survodutide
Dated, sourced reporting that mentions Survodutide.
NuScience Peptides LLC
The FDA issued a warning letter to NuScience Peptides LLC for marketing unapproved injectable peptide drugs, including GLP-1/GLP-2/GLP-3 products and other peptides, on its website. The agency determined these products are unapproved new drugs under the FD&C Act. FDA warned that failure to correct the violations could lead to seizure or injunction.
Survodutide (glucagon/GLP-1 dual agonist) cuts 16.6% weight and 63% liver fat in SYNCHRONIZE-1
Boehringer Ingelheim and Zealand Pharma's survodutide - a dual glucagon/GLP-1 receptor agonist - produced up to 16.6% mean weight loss at 76 weeks in the phase 3 SYNCHRONIZE-1 obesity trial, with a striking 34% reduction in visceral fat and a 63% reduction in liver fat versus 25% on placebo. Roughly 85% of treated patients achieved at least 5% weight loss. Published in Diabetes, Obesity and Metabolism (Wharton et al., 2025), the data differentiate survodutide on body-composition and MASLD (fatty liver) benefits rather than raw weight-loss magnitude, where it trails the triple-agonist retatrutide.
Wondering how Survodutide pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →